ESTRO 2023 - Abstract Book

S1918

Digital Posters

ESTRO 2023

Conclusion The combination of ICBT with an applicator-guided supplementary IMRT boost achieved an excellent local control and overall survival with low toxicity for bulky residual cervical tumor.

PO-2131 Results of accelerated intracavitary interventional radiotherapy schedules for cervix cancer

V. Lancellotta 1 , G. Macchia 2 , B. Fionda 1 , M. De Angeli 3 , R. Autorino 1 , M. Campitelli 1 , A. Salvati 1 , G. Ferrandina 4 , R. De Vincenzo 5 , G. Scambia 6 , M.A. Gambacorta 1 , L. Tagliaferri 1 1 Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy; 2 Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Radiation Oncology Unit, Campobasso, Italy; 3 Università di Roma, Tor Vergata, Radiation Oncology, Rome, Italy; 4 Fondazione Policlinico Universitario "A. Gemelli," Università Cattolica del Sacro Cuore, Gynecologic Oncology Unit, Rome, Italy; 5 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Gynecologic Oncology Unit, Rome, Italy; 6 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Department of Medicine and Health Sciences, Rome, Italy Purpose or Objective The standard of care for stage IB–IVA FIGO cervix cancer consists of chemo-radiation (CRT) followed by image-guided Interventional Radiotherapy (IG-IRT, also called brachytherapy) resulting in excellent local and pelvic control. Although the European brachytherapy group (GEC-ESTRO) has carried out an excellent job in attempting to standardize the contouring of volumes, dose reporting and dose constraints to the target and organs at risk, there is currently a heterogeneity in IRT timing between fractions. The aim of this study was to assess long-term intestinal, urinary, and vaginal toxicities in cervical cancer patients who underwent exclusive radio-chemotherapy followed by accelerated IG-IRT for locally advanced cervical cancer. Materials and Methods All patients underwent CRT (weekly intravenous cisplatin 40 mg/m2, 5–6 cycles, 1 day per cycle, plus 45 Gy external- beam radiotherapy (EBRT) delivered in 1.8 Gy fractions) +/- simultaneous integrated boost on positive nodes. IG-IRT schedules was as follow: First week - Day 1 - Tuesday: MRI of the pelvis, implantation, MRI of the pelvis with applicator, MRI-planning and 1st therapy session